دورية أكاديمية

Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial

التفاصيل البيبلوغرافية
العنوان: Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial
المؤلفون: Sheikh, Saira Z *, Scheinberg, Morton A, Wei, James Cheng-Chung, Tegzova, Dana, Stohl, William, de Toledo, Ricardo Acayaba, Mucenic, Tamara, Banfi, Mauricio R Abello, Maksimowicz-McKinnon, Kathleen, Abud-Mendoza, Carlos, Navarra, Sandra, Garcia, Mercedes, Garcia-De La Torre, Ignacio, Ros, Josep Ordi, Levy, Roger A, Bass, Damon L, Terrés, Jorge Ross, Punwaney, Raj, Harris, Julia, Nami, Alireza, Pierce, Amy, Thorneloe, Kevin S, Ji, Beulah, Roth, David A
المصدر: In The Lancet Rheumatology February 2021 3(2):e122-e130
قاعدة البيانات: ScienceDirect
الوصف
تدمد:26659913
DOI:10.1016/S2665-9913(20)30355-6